Tirzepatide is supplied for laboratory research workflows that require clear product identity, careful handling, and documented specifications.
Research use only. Not for human or veterinary consumption, diagnosis, or treatment.
Weight
0.050 lbs
Quantity
10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 60 MG
📊 Research Dosages and Protocols
Research phase
Research dosage
Administration frequency
Starting / Adaptation
2.5 mg
Once weekly
Primary / Maintenance
5.0 - 10.0 mg
Once weekly
Maximum exposure
15.0 mg
Once weekly
* Note: The listed dosages are based on reference research models and should be adapted to the specific requirements of your laboratory protocol.
🧫 Reconstitution and Storage
Reconstitution: Bacteriostatic Water (BAC Water) is recommended. Add it slowly down the side of the vial. Gently swirl the vial without shaking aggressively.
Storage (lyophilized powder): Store in a dark place at -20°C to 4°C.
Storage (reconstituted): After reconstitution, refrigerate at 2°C to 8°C and use within 20–30 days.
🔬 Clinical Study Results (SURMOUNT & SURPASS)
Tirzepatide has been evaluated in large phase 3 clinical studies in humans:
Weight reduction: In the SURMOUNT studies, participants achieved up to 20.9% mean body-weight loss at the highest dose.
Glycemic control: Glycated hemoglobin (HbA1c) levels decreased by more than 2.0%, with a significant improvement in insulin sensitivity.
Additional findings: Improvements in cholesterol levels and blood pressure were observed.
* Sold for laboratory research and in vitro models only. The information above summarizes findings reported in published medical literature and human clinical studies.
Frequently asked questions will be added before launch.
